Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 5, 2010, Pages 457-464

  Gerhard, Tobias ^a,b   Winterstein, Almut G ^c,d   Olfson, Mark ^e   Huang, Cecilia ^a   Saidi, Arwa ^f   Crystal, Stephen ^a  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e NONE   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adult ADHD; Cardiovascular conditions; Cardiovascular risk; Drug safety; Stimulants

Indexed keywords

ATOMOXETINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; LISDEXAMFETAMINE; METHAMPHETAMINE; PEMOLINE;

ACUTE HEART INFARCTION; ADULT; AORTA ANEURYSM; ARTERIOSCLEROSIS; ARTERY EMBOLISM; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOMYOPATHY; CEREBROVASCULAR DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DEMOGRAPHY; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM STIMULANTS; COHORT STUDIES; DRUG UTILIZATION; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPYLAMINES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77952787811     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1931     Document Type: Article

References (26)

1. Heiligenstein E, Conyers LM, Berns AR, et al. Preliminary normative data on DSM-IV attention deficit hyperactivity disorder in college students. J Am Coll Health 1998; 46: 185-188. (Pubitemid 28110429)
2. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatr 2006; 163: 716-723. DOI: 163/4/716 [pii]. 10.1176/appi.ajp.163.4.716.
3. Barkley RA, Fischer M, Smallish L, et al. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatr 2006; 45: 192-202. DOI:00004583-200602000-200700009[pii] .
4. Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatr 2006; 67: 524-540. (Pubitemid 43764229)
5. Stein MA. Impairment associated with adult ADHD. CNS Spectr 2008; 13: 9-11.
6. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatr 2006; 59: 829-835. DOI: S0006-3223(05)01207-1212[pii]. 10.1016/j.biopsych.2005.09.011.
7. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatr 2003; 53: 112-120. DOI: S0006322302016712 [pii].
8. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006; 11: 625-639. (Pubitemid 44253518)
9. Peterson K, McDonagh MS, Fu R. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology (Berl) 2008; 197: 1-11. DOI: 10.1007/s00213-007-0996-4.
10. Mosholder AD. Overview of ADHD and its pharmacotherapy, 2006. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4202 S1-01-FDA-mosholder- files/frame.htm
11. Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatr 2009; 166: 992-1001. DOI: appi.ajp.2009.09040472 [pii]. 10.1176/appi.ajp.2009.09040472.
12. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354: 1445-1448. DOI: NEJMp068049 [pii]. 10.1056/NEJMp068049.
13. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatr 2005; 66: 253-259.
14. Winterstein AG, Gerhard T, Shuster J, et al. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/ hyperactivity disorder. Pediatrics 2007; 120: e1494-e1501. DOI: 120/6/e1494 [pii]. 10.1542/peds.2007-0675.
15. Villalba L. Postmarketing safety review of sudden deaths during treatment with drugs used to treat ADHD., 2006. http://www.fda.gov/ ohrms/dockets/ac/06/ briefing/2006-4210 b-07-01-safetyreview.pdf
16. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26: 729-740. DOI: 26106 [pii]. (Pubitemid 36976134)
17. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572. DOI: 10.1001/jama.289.19.2560. 289.19.2560 [pii].
18. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913. DOI: S0140673602119118 [pii].
19. Palatini P, Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens 2004; 26: 637-644. (Pubitemid 40129752)
20. Brown DW, Giles WH, Greenlund KJ, et al. Disparities in cholesterol screening: falling short of a national health objective. Prev Med 2001; 33: 517-522. DOI: 10.1006/pmed.2001.0928. S0091-7435(01)90928-90934[pii].
21. Harrold LR, Lessard D, Yarzebski J, et al. Age and sex differences in the treatment of patients with initial acute myocardial infarction: a community-wide perspective. Cardiology 2003; 99: 39-46. DOI: 10.1159/000068445. CRD99039 [pii]. (Pubitemid 36206634)
22. Sheifer SE, Escarce JJ, Schulman KA. Race and sex differences in the management of coronary artery disease. Am Heart J 2000; 139: 848-857. DOI: S0002-8703(00)90017-90026[pii].
23. Jousilahti P, Vartiainen E, Tuomilehto J, et al. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999; 99: 1165-1172. (Pubitemid 29120088)
24. Adamson DM, Chang S, Hansen LG. White Paper: Health Research Data for the Real World: The MarketScan Databases. Ann Arbor, Mich: Thomson Medstat, July 2006.
25. Knouse LE, Cooper-Vince C, Sprich S, et al. Recent developments in the psychosocial treatment of adult ADHD. Expert Rev Neurother 2008; 8: 1537-1548. DOI: 10.1586/14737175.8.10.1537.
26. Graham J, Coghill D. Adverse effects of pharmacotherapies for attention- deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drug 2008; 22: 213-237. DOI: 2233 [pii].